Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval
Summary
Any offer, if at all, will be made only by means of the prospectus forming a part of the effective registration statement.The virus, also known as Type A H5N1 was detected for the first time in U.S. dairy cattle in March 2024. The California governor declared a state of emergency as the virus rampages through dairy cattle in that state.Seasonal influenza is estimated to represent a multi-billion antiviral market opportunity, largely driven by global health organizations, practice guidelines and government tenders, with upside potential from pandemic flu outbreaks. It has demonstrated potent in vitro activity against a range of influenza strains, including the highly pathogenic avian flu, in preclinical studies. These data, combined with good overall tolerability results in healthy subjects and prevention of lethal influenza in animal models, supports further development of Tivoxavir Marboxil as a one-time treatment for influenza.Tungsten Advisors (www.tungstenadv.com) is an investment banking firm focused on strategic advisory and corporate finance for healthcare companies. Traws has attempted to identify forward-looking statements by terminology including believes, estimates, anticipates, expects, plans, intends, may, could, might, will, should, approximately or other words that convey uncertainty of future events or outcomes.